186 related articles for article (PubMed ID: 36713413)
21. Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population.
Sirisreetreerux S; Porntharukchareon T; Dechates B; Rangsrisaeneepitak V; Therawit P; Worawitchawong S; Sornsamdang G; Soonklang K; Tawinprai K
Sci Rep; 2023 Jul; 13(1):11798. PubMed ID: 37479776
[TBL] [Abstract][Full Text] [Related]
22. A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
Baek YJ; Kim WJ; Ko JH; Lee YJ; Ahn JY; Kim JH; Jang HC; Jeong HW; Kim YC; Park YS; Kim SH; Peck KR; Shin EC; Choi JY
Vaccine; 2023 Mar; 41(10):1694-1702. PubMed ID: 36754764
[TBL] [Abstract][Full Text] [Related]
23. Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation.
Azamor T; Horbach IS; Brito E Cunha D; Melgaço JG; Silva AMVD; Tubarão LN; Azevedo AS; Santos RT; Alves NDS; Machado TL; Silva J; Souza AF; Bayma C; Rocha VP; Frederico ABT; Dias BM; Setatino BP; Denani CB; Campos SPDC; Schwarcz WD; Sucupira MV; Mendes EP; Silva EDD; Barbosa de Lima SM; Ano Bom APD; Missailidis S
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146723
[TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
[TBL] [Abstract][Full Text] [Related]
25. Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222.
Perkmann T; Perkmann-Nagele N; Mucher P; Radakovics A; Repl M; Koller T; Jordakieva G; Wagner OF; Binder CJ; Haslacher H
Int J Infect Dis; 2021 Sep; 110():309-313. PubMed ID: 34332084
[TBL] [Abstract][Full Text] [Related]
26. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD
EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342
[TBL] [Abstract][Full Text] [Related]
27. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
[TBL] [Abstract][Full Text] [Related]
28. T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.
Swanson PA; Padilla M; Hoyland W; McGlinchey K; Fields PA; Bibi S; Faust SN; McDermott AB; Lambe T; Pollard AJ; Durham NM; Kelly EJ
medRxiv; 2021 Jul; ():. PubMed ID: 34189538
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis.
Parry H; Bruton R; Tut G; Ali M; Stephens C; Greenwood D; Faustini S; Hughes S; Huissoon A; Meade R; Brown K; Amirthalingam G; Otter A; Hallis B; Richter A; Zuo J; Moss P
Lancet Healthy Longev; 2021 Sep; 2(9):e554-e560. PubMed ID: 34401865
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
Koen AL; Izu A; Baillie V; Kwatra G; Cutland CL; Fairlie L; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Ahmed K; Bhikha S; Bhiman JN; du Plessis J; Esmail A; Horne E; Hwa SH; Oommen-Jose A; Lambe T; Laubscher M; Malahleha M; Benade G; McKenzie S; Oelofse S; Patel F; Pillay S; Rhead S; Rodel H; Taoushanis C; Tegally H; Thombrayil A; Villafana TL; Gilbert S; Pollard AJ; Madhi SA
Vaccine; 2023 May; 41(23):3486-3492. PubMed ID: 37149443
[TBL] [Abstract][Full Text] [Related]
31. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 Spike Protein Expression
Stebbings R; Jones C; Cotton P; Armour G; Maguire S; Skellett V; Tang CM; Goodman J; Brady T; Takahashi V; Daunt A; Lapointe JM; Cohen TS
Front Immunol; 2022; 13():836492. PubMed ID: 35493482
[TBL] [Abstract][Full Text] [Related]
33. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Kaplonek P; Cizmeci D; Kwatra G; Izu A; Lee JS; Bertera HL; Fischinger S; Mann C; Amanat F; Wang W; Koen AL; Fairlie L; Cutland CL; Ahmed K; Dheda K; Barnabas SL; Bhorat QE; Briner C; Krammer F; Saphire EO; Gilbert SC; Lambe T; Pollard AJ; Nunes M; Wuhrer M; Lauffenburger DA; Madhi SA; Alter G
Nat Immunol; 2023 Jul; 24(7):1161-1172. PubMed ID: 37322179
[TBL] [Abstract][Full Text] [Related]
34. Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals.
Patil R; Shanbhag S; Shankarkumar A; Madkaikar M
Indian J Med Res; 2022; 155(5&6):538-545. PubMed ID: 36124500
[TBL] [Abstract][Full Text] [Related]
35. A linear B-cell epitope close to the furin cleavage site within the S1 domain of SARS-CoV-2 Spike protein discriminates the humoral immune response of nucleic acid- and protein-based vaccine cohorts.
Lorenz P; Steinbeck F; Mai F; Reisinger EC; Müller-Hilke B
Front Immunol; 2023; 14():1192395. PubMed ID: 37228598
[TBL] [Abstract][Full Text] [Related]
36. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
Jarius S; Bieber N; Haas J; Wildemann B
J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
[TBL] [Abstract][Full Text] [Related]
37. Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine.
Sureshchandra S; Lewis SA; Doratt BM; Jankeel A; Coimbra Ibraim I; Messaoudi I
JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34935643
[TBL] [Abstract][Full Text] [Related]
38. Antigen specific T cells in people with obesity at five months following ChAdOx1 COVID-19 vaccination.
Kelly NEW; De Barra C; Shaamile F; Holland A; Shaw L; Mallon PWG; O'Connell J; Hogan AE; O'Shea D
Int J Obes (Lond); 2023 Jan; 47(1):83-86. PubMed ID: 36347936
[TBL] [Abstract][Full Text] [Related]
39. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Byrne F; Cerrone M; Schmitt AM; Joharatnam-Hogan N; Shum B; Tippu Z; Rzeniewicz K; Boos LA; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Sarker S; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Bazin J; Gordon W; Barber T; Emslie-Henry A; Xie W; Gerard CL; Deng D; Wall EC; Agua-Doce A; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Dowdie L; Ash N; Gronthoud F; Shea RL; Gardner G; Murray D; Kinnaird F; Cui W; Pascual J; Rodney S; Mencel J; Curtis O; Stephenson C; Robinson A; Oza B; Farag S; Leslie I; Rogiers A; Iyengar S; Ethell M; Messiou C; Cunningham D; Chau I; Starling N; Turner N; Welsh L; van As N; Jones RL; Droney J; Banerjee S; Tatham KC; O'Brien M; Harrington K; Bhide S; Okines A; Reid A; Young K; Furness AJS; Pickering L; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Kumar S; Yousaf N; Jhanji S; Nicholson E; Howell M; Walker S; Wilkinson RJ; Larkin J; Turajlic S;
Nat Cancer; 2021 Dec; 2(12):1305-1320. PubMed ID: 35121899
[TBL] [Abstract][Full Text] [Related]
40. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2.
Vogel E; Kocher K; Priller A; Cheng CC; Steininger P; Liao BH; Körber N; Willmann A; Irrgang P; Held J; Moosmann C; Schmidt V; Beileke S; Wytopil M; Heringer S; Bauer T; Brockhoff R; Jeske S; Mijocevic H; Christa C; Salmanton-García J; Tinnefeld K; Bogdan C; Yazici S; Knolle P; Cornely OA; Überla K; Protzer U; Schober K; Tenbusch M
EBioMedicine; 2022 Nov; 85():104294. PubMed ID: 36206622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
